Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,138.81 USD
-7.94 (-0.69%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $1,140.43 +1.62 (0.14%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
REGN 1,138.81 -7.94(-0.69%)
Will REGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REGN
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
Other News for REGN
JMP Securities healthcare analysts hold an analyst/industry conference call
Buy Rating Affirmed: Regeneron’s Growth Potential Anchored by Strong Pipeline and Market Performance
RBC Capital Reaffirms Their Buy Rating on Regeneron (REGN)
Analyst Issues Sell Rating for Regeneron Amid Competitive Challenges and Limited Market Potential
IN BRIEF: Sanofi and Regeneron show Dupixent treats bullous pemphigoid